Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

BeiGene Starts China Trial of PARP Inhibitor in Ovarian Cancer Patients

publication date: May 18, 2018

BeiGene, a Beijing oncology company, has enrolled the first patient in a China Phase III trial of pamiparib (BGB-290), a PARP inhibitor, in patients with platinum-sensitive recurrent ovarian cancer. The drug will be administered as a maintenance therapy in patients whose ovarian cancer has recurred. Pamiparib is also being tested as a monotherapy and in combination regimens for a variety of solid tumor malignancies. BeiGene pointed out that, to date, there are no PARP inhibitors approved for China use. More details....

Stock Symbol: (NSDQ: BGNE)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.